Ben Samelson-Jones: Long-Term Safety and Efficacy of AAV Gene Therapy Using FIX-Padua in Hemophilia B
Ben Samelson-Jones, Associate Director of Clinical In Vivo Gene Therapy at Children’s Hospital of Philadelphia and Assistant Professor of Pediatrics at University of Pennsylvania School of Medicine, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Sustained long term safety and efficacy (up to 6 years) with AAV gene therapy using FIX-Padua for hemophilia B.”
Title: Safety, efficacy and patient-reported outcomes 6 years after fidanacogene elaparvovec in adults with hemophilia B
Authors: Benjamin J Samelson-Jones, John EJ Rasko, Jonathan Ducore, Catherine McGuinn, Lindsey A. George, Sylvia von Mackensen, Gianluca Borgonuovo, Delphine Agathon, Lynne Smith, Lisa J Wilcox, Francesca Biondo, Frank Plonski
Read the Full Article on Blood Advances

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 15, 2026, 20:56Victoria Adedoyin Adisa-Thomas: What I Learned About SCD During My Genetic Counselling Rotation
-
Nov 15, 2026, 20:55Martin Holst Lange: One Step Closer to a Potential New Treatment for Sickle Cell Disease
-
Nov 15, 2026, 20:53Bontha Babu: Health-Related Quality of Life Among Adults with Sickle Cell Disease in India
-
Nov 15, 2026, 20:52Miguel Ángel Herrera Rojas: A First-Line ITP Approach Presented at ASH in 2013 Now Reflected in the 2026 Guidelines
-
Nov 15, 2026, 20:50Asmaa Beltagy: Efficacy and Safety of Eltrombopag in SLE-Associated Immune Thrombocytopenia
-
Nov 15, 2026, 16:29Jean-Jacques Kiladjian: 20 Years of Interferon-Alpha Research in Myeloproliferative Neoplasms
-
Nov 15, 2026, 16:21Sukanto Paul: Why Platelet Transfusion Is Generally Avoided in TTP
-
Nov 15, 2026, 16:14Ahmad G. Alzahrani: Major Bleeding and Anticoagulant Reversal
-
Nov 15, 2026, 16:05Sabine Eichinger: Is Recurrence Risk After Provoked VTE Really Low?